Featured Research

from universities, journals, and other organizations

No More Seizures? New Drug Holds Promise For Epilepsy Patients

Date:
February 6, 2007
Source:
American Academy of Neurology
Summary:
People with newly diagnosed epilepsy experienced few, if any, seizures while taking the drug levetiracetam as a single therapy, giving hope to epilepsy patients who don't respond to or can't tolerate existing treatments, according to a study published in the Feb. 6, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.

People with newly diagnosed epilepsy experienced few, if any, seizures while taking the drug levetiracetam as a single therapy, giving hope to epilepsy patients who don't respond to or can't tolerate existing treatments, according to a study published in the February 6, 2007 issue of Neurology, the scientific journal of the American Academy of Neurology.

For the multi-center, double-blind study, researchers assigned nearly 600 adults who had at least two seizures in the previous year to the drug levetiracetam or to controlled-release carbamazepine, a common epilepsy treatment. While levetiracetam is currently used as an add-on therapy by epilepsy patients, this is the first time its effectiveness as a single therapy has been tested through a clinical trial that provided class 1 evidence of efficacy as defined by the International League Against Epilepsy.

The study found 73 percent of people taking levetiracetam and 72.8 percent of people receiving controlled-release carbamazepine remained seizure free for at least six months.

"Both drugs produced equivalent seizure freedom rates in newly diagnosed epilepsy. Levetiracetam helps fill a need for safe and well-tolerated, easy-to-use epilepsy drugs, particularly because more than 30 percent of patients do not achieve seizure control with existing treatments," said study author Martin Brodie, MD, with the Western Infirmary Epilepsy Unit in Glasgow, Scotland.

Of those remaining seizure free for six months, the study also found 80.1 percent of those taking levetiracetam and 85.4 percent of those taking carbamazepine did so at the lowest dose level.

"This trial confirms previous uncontrolled observations that most people with epilepsy will respond to their first epilepsy drug at low dosage," said Brodie.

Researchers say 14.4 percent of people taking levetiracetam withdrew from the study because of side effects such as drowsiness or dizziness, while 19.2 percent of people taking carbamazepine withdrew from the study with rash being the most common side effect.

The study was supported by UCB Pharma.


Story Source:

The above story is based on materials provided by American Academy of Neurology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Neurology. "No More Seizures? New Drug Holds Promise For Epilepsy Patients." ScienceDaily. ScienceDaily, 6 February 2007. <www.sciencedaily.com/releases/2007/02/070206095919.htm>.
American Academy of Neurology. (2007, February 6). No More Seizures? New Drug Holds Promise For Epilepsy Patients. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2007/02/070206095919.htm
American Academy of Neurology. "No More Seizures? New Drug Holds Promise For Epilepsy Patients." ScienceDaily. www.sciencedaily.com/releases/2007/02/070206095919.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

EU Ministers and Experts Meet to Discuss Ebola Reponse

EU Ministers and Experts Meet to Discuss Ebola Reponse

AFP (Sep. 15, 2014) The European Commission met on Monday to coordinate aid that the EU can offer to African countries affected by the Ebola outbreak. Duration: 00:58 Video provided by AFP
Powered by NewsLook.com
Despite The Risks, Antibiotics Still Overprescribed For Kids

Despite The Risks, Antibiotics Still Overprescribed For Kids

Newsy (Sep. 15, 2014) A new study finds children are prescribed antibiotics twice as often as is necessary. Video provided by Newsy
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Respiratory Virus Spreads To Northeast, Now In 21 States

Respiratory Virus Spreads To Northeast, Now In 21 States

Newsy (Sep. 14, 2014) The respiratory virus Enterovirus D68, which targets children, has spread from the Midwest to 21 states. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins